Several recent examples illustrate the problems of trusting drug companies to provide the complete picture about the clinical trials they sponsor. Robert Steinbrook and Jerome P Kassirer propose that there is a strong case for journals defining full access to the trial data and requiring that investigators and journal editors have full access.